Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jieyinling Xiji is a Traditional Chinese Medicine (TCM) topical antibacterial wash developed and marketed by Shenqi Pharmaceutical. It is formulated with several herbal extracts, including *Sophora flavescens* (Ku Shen), *Phellodendron amurense* (Huang Bai), *Cnidium monnieri* (She Chuang Zi), and *Artemisia argyi* (Ai Ye). These ingredients provide broad-spectrum antibacterial, antifungal, and anti-inflammatory properties. The product is primarily indicated for gynecological hygiene and the treatment of conditions such as vulvovaginitis, pruritus vulvae, and various skin infections. It is applied topically as a wash to cleanse the affected area and alleviate symptoms like itching and discharge. The drug is approved and marketed in China by Guizhou Shenqi Pharmaceutical, which is listed on the Shanghai Stock Exchange.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jieyinling Xiji.